ClinicalTrials.gg
CompletedNCT05925127COVID-19Updated Dec 13, 2024

Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines

A Phase 2/3 interventional study of NVX-CoV2373 (5μg) and NVX-CoV2601 (5μg) in COVID-19, sponsored by Novavax. Completed at 50 sites in United States. Open to participants aged 50 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-13.

Sponsored by Novavax · Phase 2/3, Interventional, and Prevention

From the registry’s dates

  • Primary completion was May 2024, 2 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
994
Allocation
Randomized
Ages
50 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19 — none open to participants now, 2 under way, none of them phase 3. NVX-CoV2373 adjuvated lipid nanoparticle · COVID-19.

Enrollment
10th of 18
994 · median 997
Started
2023
with 3 others
Phase 2/3
2 of 18
none open now
Registered
12th of 18
by date
Lead sponsor
12 of 18
Novavax

Among the 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19, this one is the 10th largest by enrollment, is one of 4 that started in 2023, is one of 2 in phase 2/3, and was the 12th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

None of the 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19 is open now. The open studies under COVID-19, anywhere →

About NVX-CoV2373 adjuvated lipid nanoparticle

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 50 Years to 99 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19 as a file.
02

Study summary

This is a Phase 2/3, randomized, double-blind study to evaluate the safety and immunogenicity of different booster dose levels of the monovalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant (r) spike (S) protein nanoparticle (SARS-CoV-2 rS) vaccines with Matrix-M™ adjuvant (NVX-CoV2373 [prototype Wuhan vaccine with Matrix-M adjuvant] or NVX-CoV2601 [Omicron XBB.1.5 subvariant vaccine with Matrix-M adjuvant]).

Read the detailed description

The ongoing COVID-19 pandemic has reached a stage where it is necessary to stablish the framework for periodic national vaccination campaigns.The present study aims to investigate the safety and immunogenicity of different booster dose levels of monovalent and bivalent vaccines in adults ≥ 50 years of age who have already been immunized with ≥ 3 doses of a COVID-19 prototype or bivalent licensed mRNA vaccine. The Boosters of investigational products will be administered ≥ 90 days after the participants received their third dose of a COVID-19 prototype or bivalent licensed mRNA vaccine.

Approximately 1,980 participants ≥ 50 years of age who have received a regimen of ≥ 3 doses of a coronavirus disease 2019(COVID-19) vaccine (the last vaccine could have been a bivalent licensed mRNA vaccine) will be included in this study. The last COVID-19 vaccine dose should have been administered ≥ 90 days prior to Day 0.

Approximately 1,800 participants will be randomly assigned in a 1:2:2:2:2:1 ratio to receive NVX-CoV2373 or NVC-CoV2601 in a double-blinded fashion into 1 of 6 monovalent vaccine groups (vaccine groups A to G). Following completion of enrollment into the 6 monovalent vaccine groups, 180 participants will be enrolled in vaccine group G to receive a bivalent licensed mRNA vaccine in an open-label fashion.

03

Conditions studied

  • COVID-19

Browse trials for

04

Who can participate

Ages eligible
50 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults ≥ 50 years of age at screening.
  2. Willing and able to give prior to study enrollment and to comply with study procedures.
  3. Female participants of (defined as any participant who has experienced menarche and who is NOT surgically sterile [ie, hysterectomy, bilateral tubal ligation, or bilateral oophorectomy] or [defined as amenorrhea ≥ 12 consecutive months]) must agree to be heterosexually inactive from at least 28 days prior to enrollment and through the end of the study OR agree to consistently use a medically acceptable method of listed below from ≥ 28 days prior to enrollment and through the end of the study.
  4. Is medically stable, as determined by the investigator (based on review of health status, vital signs [to include body temperature], medical history, and targeted physical examination [to include body weight]). Vital signs must be within medically acceptable ranges prior to the initial study vaccination.
  5. Agrees to not participate in any other SARS-CoV-2 prevention or treatment trials for the duration of the study.
  6. Have previously received ≥ 3 doses of a COVID-19 prototype or bivalent licensed mRNAvaccine with the last dose having been given ≥ 90 days previously prior to first study booster.

Exclusion criteria

Exclusion Criteria:

  1. Received COVID-19 vaccines other than a COVID-19 prototype or bivalent licensed mRNA vaccine in the past, inclusive of clinical trial COVID-19 vaccines.
  2. Participation in research involving receipt of products (drug/biologic/device) within 90 days prior to study vaccination.
  3. Received influenza vaccination within 14 days prior to first study vaccination, or any other vaccine within 30 days prior to first study vaccination.
  4. Any known allergies to products contained in the investigational product. 5. Any history of anaphylaxis to any prior vaccine.
  1. or immunodeficiency disease/condition (iatrogenic or congenital) requiring ongoing immunomodulatory therapy.
  1. Chronic administration (defined as > 14 continuous days) of , systemic , or other immune-modifying drugs within 90 days prior to study vaccination. NOTE: An immunosuppressant dose of glucocorticoid is defined as a systemic dose ≥ 10 mg of prednisone per day or equivalent. The use of topical or intranasal glucocorticoids is permitted. Topical tacrolimus and ocular cyclosporin are permitted. Use of inhaled glucocorticoids is prohibited.
  1. Received immunoglobulin, blood-derived products, or immunosuppressant drugs within 90 days prior to study vaccination, except for rabies immunoglobulin which may be given if medically indicated.
  1. Active cancer () on therapy within 3 years prior to study vaccination (with the exception of adequately treated non-melanomatous skin carcinoma or lentigo maligna and uterine cervical carcinoma in situ without evidence of disease, at the discretion of the investigator).
  1. Participants who are breastfeeding, pregnant, or who plan to become pregnant prior to the end of study.
  1. Suspected or known history of alcohol abuse or drug addiction within 2 years prior to the study vaccine dose that, in the opinion of the investigator, might interfere with protocol compliance.
  1. Any other condition that, in the opinion of the investigator, would pose a health risk to the participant if enrolled or could interfere with evaluation of the study vaccine or interpretation of study results (including neurologic or psychiatric conditions likely to impair the quality of safety reporting).
  1. Study team member or immediate family member of any study team member (inclusive of Sponsor, contract research organization (CRO), and study site personnel involved in the conduct or planning of the study).
  1. Participants with a history of myocarditis or pericarditis.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
994 participants (actual)

Study arms

  • Experimental
    Group-A Monovalent NVX-CoV2373 (5 μg)

    The Monovalent NVX-CoV2601 of 5 μg of antigen with 50 μg of Matrix-M adjuvant

    Biological: NVX-CoV2373 (5μg)

  • Experimental
    Group-B Monovalent NVX-CoV2601 (5 μg)

    Monovalent NVX-CoV2601 (5 μg of antigen with 50 μg of Matrix-M adjuvant)

    Biological: NVX-CoV2601 (5μg)

  • Experimental
    Group-C Monovalent NVX-CoV2601 (5 μg)

    Monovalent NVX-CoV2601 (5 μg of antigen with 75 μg of Matrix-M adjuvant)

    Biological: NVX-CoV2601(5μg)

  • Experimental
    Group-D Monovalent NVX-CoV2601 (35 μg)

    Monovalent NVX-CoV2373 (35 μg of antigen with 50 μg of Matrix-M adjuvant)

    Biological: NVX-CoV2601 (35μg)

  • Experimental
    Group-E Monovalent NVX-CoV2601(35)

    Monovalent NVX-CoV2601 (35 μg of each antigen with a 75 μg of Matrix-M adjuvant)

    Biological: NVX-CoV2601(35μg)

  • Experimental
    Group-F Monovalent NVX-CoV2601 (50 μg)

    Monovalent NVX-CoV2601 (50 μg of each antigen with a 100 μg of Matrix-M adjuvant)

    Biological: NVX-CoV2601(50μg)

  • Experimental
    Group-G Bivalent XBB.1.5

    Bivalent XBB.1.5 Omicron subvariant/prototype COVID-19 licensed mRNA vaccine

    Biological: Bivalent BA.4/5

Interventions

  • Coformulated prototype SARS-CoV-2 rS vaccine with Matrix-M adjuvant: supplied as a solution for preparation for injection, at a concentration of 10 μg/mL and 100 μg adjuvant per mL, respectively

  • BiologicalNVX-CoV2601 (5μg)

    The vaccination regimen will comprise one IM injection on Day 0 at a dose of 5 µg of antigen with 50 µg Matrix-M adjuvant.

    Also known as: Omicron XBB.1.5

  • BiologicalNVX-CoV2601(5μg)

    The vaccination regimen will comprise one IM injection on Day 0 at a dose of 5 µg of antigen with 75 µg Matrix-M adjuvant.

    Also known as: Omicron XBB.1.5

  • BiologicalNVX-CoV2601 (35μg)

    The vaccination regimen will comprise one IM injection on Day 0 at a dose of 35 µg of antigen with 50 µg Matrix-M adjuvant.

    Also known as: Omicron XBB.1.5

  • BiologicalNVX-CoV2601(35μg)

    The vaccination regimen will comprise one IM injection on Day 0 at a dose of 35 µg of antigen with 75 µg Matrix-M adjuvant.

    Also known as: Omicron XBB.1.5

  • BiologicalNVX-CoV2601(50μg)

    The vaccination regimen will comprise one IM injection on Day 0 at a dose of 50 µg of antigen with 100 µg Matrix-M adjuvant

    Also known as: Omicron XBB.1.5

  • BiologicalBivalent BA.4/5

    The bivalent BA.4/5 (or recommended mRNA vaccine at the time of the conduct of this study) Omicron subvariant/prototype licensed mRNA vaccine will be procured and stored per the manufacturer's instructions. For this vaccine group, treatment will be administered open label as a single IM injection

    Also known as: Omicron Subvariant/Prototype Licensed mRNA Vaccine

06

What researchers measure

Primary outcomes

  1. Immunogenicity index-Neutralizing antibody expressed as geometric mean titer ratio[GMTR ]against the Omicron subvariant XBB.1.5

    Neutralizing antibody To determine if the combination of antigen and adjuvant levels of NVX-CoV2601 GMTR against the Omicron subvariant XBB.1.5 superior(LB of the 95% CI for GMTR \> 1.0) to that elicited by NVX-CoV2373

    Time frame: Day 28

  2. Immunogenicity index-Neutralizing antibody expressed as seroresponse rates (SRRs)against the Omicron subvariant XBB.1.5

    Neutralizing antibody SRR against the Omicron XBB.1.5 subvariant elicited by NVXCoV2601 is non-inferior (NI)to the SRR elicited by NVX-CoV2373in participants ≥ 50 years of age previously vaccinated with ≥ 3 doses of a COVID-19 prototype or bivalent licensed mRNA vaccine.

    Time frame: Day 28

Secondary outcomes

  1. Neutralizing antibody expressed as geometric mean titer ratio[GMTR ]against the Omicron subvariant XBB.1.5

    Neutralizing antibody (GMTR) at relevant time points Days 28 to 180 from baseline (Day 0) and analyzed by dose (5, 10, and 25 µg)

    Time frame: Day 28

  2. Immunogenicity index- IgG antibody Anti-S expressed as geometric mean Elisa units GMEUs (EU/mL)

    Immunoglobulin G (IgG) antibody Anti-S expressed as geometric mean Elisa units GMEUs (EU/mL) at relevant time points (Days 0 to 180) and analyzed by dose (5, 10, and 25 µg)

    Time frame: Day 0 to 180

  3. Immunogenicity index- Neutralizing antibody titers of post-booster by baseline anti-SARS-CoV-2 NP

    Neutralizing antibody titers of post-booster by baseline anti-SARS-CoV-2 NP status day-28

    Time frame: Day-28

  4. Immunogenicity index- Serum IgG levels to SARS-CoV-2 S protein at Day 28 of post-booster

    Serum IgG levels to SARS-CoV-2 S protein at Day 28 post-booster by baseline anti-SARS-CoV-2 NP status.

    Time frame: Day-28

  5. Safety Index-Incidence, duration, and severity of solicited local and systemic AEs expressed as GMT

    Incidence, duration, and severity of solicited local and systemic AEs for 7 days following vaccination.

    Time frame: 7 days

  6. Safety Index -Incidence and relationship of Medically Attended Adverse Event(s) (MAAEs), Adverse event(s) of Special Interest (AESIs), and Serious Adverse Event(s) (SAEs)

    Incidence and relationship of Medically Attended Adverse Event(s) (MAAEs), Adverse event(s) of Special Interest (AESIs), and Serious Adverse Event(s) (SAEs) \[ Time Frame: Day 0 to Day 180 \] Incidence and relationship of MAAEs, AESIs (predefined list), and SAEs throughout the study

    Time frame: Day 0 to 180

  7. Safety Index -Incidence, Severity, and relationship of unsolicitated Adverse Event(s) Through 28 days after vaccination by vaccine group p(vaccine groups A to G).

    Incidence, Severity, and relationship of unsolicitated Adverse Event(s) Through 28 days after vaccination by vaccine group p(vaccine groups A to G).s the overall safety of single-dose regimens containing NVX-CoV2601, NVX-CoV2373, or mRNA vaccine by vaccine group in participants ≥ 50 years of age previously vaccinated with ≥ 3 doses of a COVID-19 prototype or bivalentlicensed mRNA vaccine.

    Time frame: Day 0 to 180

  8. Human angiotensin-converting enzyme 2 (hACE2) receptor binding inhibition assay to the ancestral (Wuhan), Omicron BA.1, and Omicron BA.5 viruses expressed as GMTs

    hACE2 receptor binding inhibition assay to the ancestral (Wuhan), Omicron BA.1, and Omicron BA.5 viruses at relevant time points (Days 0, 28, and 180) and analyzed by dose (5, 10, and 25 µg)

    Time frame: Day 0 to 180

  9. hACE2 receptor binding inhibition assay to the ancestral (Wuhan), Omicron BA.1, and Omicron BA.5 viruses expressed as GMFR

    hACE2 receptor binding inhibition assay to the ancestral (Wuhan), Omicron BA.1, and Omicron BA.5 viruses at relevant time points (Days 0, 28, and 180) and analyzed by dose (5, 10, and 25 µg).

    Time frame: Day 0 to 180

  10. hACE2 receptor binding inhibition assay to the ancestral (Wuhan), Omicron BA.1, and Omicron BA.5 S proteins expressed as SRR

    hACE2 receptor binding inhibition assay to the ancestral (Wuhan), Omicron BA.1, and Omicron BA.5 S proteins at relevant time points (Days 0, 28, and 180)and analyzed by previous vaccine combination received. Derived/calculated endpoints based on these data will include SRRs.

    Time frame: Day 0 to 180

07

Study locations

50 sites
  • ARS-Birmingham CRU
    Birmingham, Alabama 35216, United States
  • Tucson Neuroscience Research
    Tucson, Arizona 85710, United States
  • Velocity Clinical Research, Banning
    Banning, California 99202, United States
  • Velocity Clinical Research, Chula Vista
    Chula Vista, California 91911, United States
  • Velocity Clinical Research, San Diego
    La Mesa, California 91942, United States
  • Artemis Institute for Clinical Research
    Riverside, California 92503, United States
  • Artemis - San Diego
    San Diego, California 92103, United States
  • WR-MCCR
    San Diego, California 92120, United States
  • Deland CRU
    DeLand, Florida 32720, United States
  • Health Awareness
    Jupiter, Florida 33458, United States
  • Wr-Msra, Llc
    Lake City, Florida 32055, United States
  • Professional Urgent Care Services
    Largo, Florida 33777, United States
  • Research Institute of South Florida
    Miami, Florida 33173, United States
  • Suncoast Research Associates, LLC
    Miami, Florida 33173, United States
  • Headlands Research Orlando LLC
    Orlando, Florida 32819, United States
  • Precision Clinical Research, LLC
    Sunrise, Florida 33351, United States
  • TrueBlue Clinical Research
    Tampa, Florida 33609, United States
  • Neurostudies CRU
    Decatur, Georgia 30030, United States
  • Velocity Clinical Research
    Savannah, Georgia 31406, United States
  • CRA Headlands LLC
    Stockbridge, Georgia 30281, United States
  • Velocity Clinical Research
    Meridian, Idaho 83642, United States
  • Velocity Clinical Research
    Sioux City, Iowa 51106, United States
  • Velocity Clinical Research
    Baton Rouge, Louisiana 70809, United States
  • Velocity Clinical Research - Covington
    Covington, Louisiana 70433, United States
  • Velocity Clinical Research, Metairie
    Metairie, Louisiana 70006, United States
  • Activmed Practices and Research, LLC
    Methuen, Massachusetts 01844, United States
  • Velocity Clinical Research, Gulfport
    Gulfport, Mississippi 39503, United States
  • Velocity Clinical Research
    Grand Island, Nebraska 68803, United States
  • Velocity Clinical Research
    Norfolk, Nebraska 68701, United States
  • Velocity Clinical Research
    Omaha, Nebraska 68134, United States
  • Activmed Practices and Research, LLC
    Portsmouth, New Hampshire 03801, United States
  • Velocity Clinical Research
    Binghamton, New York 13905, United States
  • Hypercore (Lucas Research)
    New Bern, North Carolina 28562, United States
  • M3 Wake Research Inc
    Raleigh, North Carolina 27612, United States
  • Trial Management Associates, LLC
    Wilmington, North Carolina 28403, United States
  • Javara Inc./Wake Forest Health Network, LLC
    Winston-Salem, North Carolina 27157, United States
  • Velocity Clinical Research
    Cincinnati, Ohio 45219, United States
  • Velocity Clinical Research
    Cincinnati, Ohio 45246, United States
  • Tekton Research
    Edmond, Oklahoma 73013, United States
  • Lynn Health Science Institute
    Oklahoma City, Oklahoma 73112, United States
  • Velocity Clinical Research, Grants Pass
    Grants Pass, Oregon 97527, United States
  • Velocity Clinical Research, Providence
    East Greenwich, Rhode Island 02818, United States
  • Velocity Clinical Research, Gaffney
    Gaffney, South Carolina 29340, United States
  • Coastal Carolina Research Center an ALCANZA Clinical Research company
    North Charleston, South Carolina 29405, United States
  • Central Texas Clinical Research, LLC
    Austin, Texas 78705, United States
  • Research Your Health
    Plano, Texas 75093, United States
  • Benchmark Research
    San Angelo, Texas 76904, United States
  • Velocity Clinical Research, Salt Lake City
    West Jordan, Utah 84088, United States
  • Health Research of Hampton Roads, Inc
    Newport News, Virginia 23606, United States
  • Clinical Research Partners
    Richmond, Virginia 23226, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in May 2024, 7 months.

Of 73 industry-sponsored phase 2/3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 7 months is below that.

Counting every sponsor, half of 168 studies reached it within 11 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2023
First posted
Jun 29, 2023
StartActual
Oct 16, 2023
Primary completionActual
May 21, 2024
CompletionActual
May 21, 2024
Last update
Dec 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05925127
Lead sponsor
Novavax
Responsible party
Sponsor
First posted
Jun 29, 2023
Start date
Oct 16, 2023
Primary completion
May 21, 2024
Completion
May 21, 2024
Last update
Dec 13, 2024

Study contacts

Clinical Development
study director · Novavax

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NVX-CoV2373 adjuvated lipid nanoparticle

Start the discussion